Statin Conversion Calculator<\/title>\n <style>\n \/* Basic Reset and Styling *\/\n * {\n box-sizing: border-box;\n margin: 0;\n padding: 0;\n }\n body {\n font-family: Arial, sans-serif;\n background-color: #f4f4f9;\n padding: 20px;\n }\n .calculator-container {\n max-width: 600px;\n margin: 0 auto;\n padding: 25px;\n background: #fff;\n border-radius: 10px;\n box-shadow: 0 2px 10px rgba(0,0,0,0.1);\n }\n h1, h2 {\n text-align: center;\n color: #333;\n margin-bottom: 20px;\n }\n label {\n display: block;\n font-weight: bold;\n margin-top: 15px;\n color: #333;\n }\n select {\n width: 100%;\n padding: 10px;\n margin-top: 5px;\n margin-bottom: 15px;\n border: 1px solid #ccc;\n border-radius: 5px;\n font-size: 16px;\n }\n .button-row {\n display: flex;\n justify-content: space-between;\n gap: 10px;\n margin-top: 20px;\n }\n button {\n flex: 1;\n padding: 12px 0;\n background-color: #0073aa;\n color: white;\n border: none;\n border-radius: 5px;\n font-size: 16px;\n cursor: pointer;\n transition: background-color 0.3s ease;\n }\n button:hover {\n background-color: #005177;\n }\n .results-container {\n margin-top: 30px;\n padding: 20px;\n background: #f9f9f9;\n border-radius: 8px;\n text-align: center;\n display: none;\n }\n .result-label {\n font-weight: bold;\n color: #333;\n margin-top: 10px;\n }\n .result-value {\n font-size: 20px;\n color: #d9534f;\n margin-bottom: 15px;\n }\n @media (max-width: 600px) {\n .button-row {\n flex-direction: column;\n }\n button {\n margin-top: 10px;\n }\n }\n <\/style>\n<\/head>\n<body data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1>\n\n<div class=\"calculator-container\">\n <h1>Statin Conversion Calculator<\/h1>\n <div id=\"form-container\">\n <h2>Select LDL Reduction and Statin Drug<\/h2>\n \n \n <label for=\"ldlRange\">%LDL Reduction Range<\/label>\n <select id=\"ldlRange\">\n <option value=\"\">–Select LDL Reduction Range–<\/option>\n <option value=\"<24\">Less than 24%<\/option>\n <option value=\"25-32\">25\u201332%<\/option>\n <option value=\"31-39\">31\u201339%<\/option>\n <option value=\"37-49\">37\u201349%<\/option>\n <option value=\"49-52\">49\u201352%<\/option>\n <option value=\"55-60\">55\u201360%<\/option>\n <option value=\"60-63\">60\u201363%<\/option>\n <\/select>\n \n \n <label for=\"statinDrug\">Statin Drug<\/label>\n <select id=\"statinDrug\">\n <option value=\"\">–Select Statin Drug–<\/option>\n <option value=\"simvastatin\">Simvastatin (Zocor)<\/option>\n <option value=\"atorvastatin\">Atorvastatin (Lipitor)<\/option>\n <option value=\"rosuvastatin\">Rosuvastatin (Crestor)<\/option>\n <option value=\"fluvastatin\">Fluvastatin (Lescol)<\/option>\n <option value=\"lovastatin\">Lovastatin (Mevacor)<\/option>\n <option value=\"pravastatin\">Pravastatin (Pravachol)<\/option>\n <option value=\"ezetimibe-simvastatin\">Ezetimibe + Simvastatin (Vytorin)<\/option>\n <\/select>\n \n \n <div class=\"button-row\">\n <button id=\"calculateBtn\" type=\"button\">Show Estimated Dose<\/button>\n <button id=\"resetBtn\" type=\"button\">Reset<\/button>\n <\/div>\n <\/div>\n \n \n <div class=\"results-container\" id=\"resultsContainer\">\n <h2>Estimated Statin Dose<\/h2>\n <div class=\"results\">\n <p class=\"result-label\">Selected %LDL Reduction Range:<\/p>\n <div class=\"result-value\" id=\"selectedLDL\">—<\/div>\n \n <p class=\"result-label\">Selected Statin Drug:<\/p>\n <div class=\"result-value\" id=\"selectedStatin\">—<\/div>\n \n <p class=\"result-label\">Recommended Dose:<\/p>\n <div class=\"result-value\" id=\"doseResult\">—<\/div>\n <\/div>\n <div class=\"button-row\">\n <button id=\"backBtn\" type=\"button\">Back<\/button>\n <button id=\"resetResultsBtn\" type=\"button\">Reset<\/button>\n <\/div>\n <\/div>\n<\/div>\n\n<script>\n \/**\n * Data Mapping for %LDL Reduction and Statin Doses\n *\/\n const statinDoseData = {\n \"<24\": {\n \"simvastatin\": \"5 mg\",\n \"atorvastatin\": \"N\/A\",\n \"rosuvastatin\": \"N\/A\",\n \"fluvastatin\": \"20 mg\",\n \"lovastatin\": \"10 mg\",\n \"pravastatin\": \"10 mg\",\n \"ezetimibe-simvastatin\": \"N\/A\"\n },\n \"25-32\": {\n \"simvastatin\": \"10 mg\",\n \"atorvastatin\": \"N\/A\",\n \"rosuvastatin\": \"N\/A\",\n \"fluvastatin\": \"40 mg\",\n \"lovastatin\": \"20 mg\",\n \"pravastatin\": \"20 mg\",\n \"ezetimibe-simvastatin\": \"N\/A\"\n },\n \"31-39\": {\n \"simvastatin\": \"20 mg\",\n \"atorvastatin\": \"10 mg\",\n \"rosuvastatin\": \"N\/A\",\n \"fluvastatin\": \"80 mg\",\n \"lovastatin\": \"40 mg\",\n \"pravastatin\": \"40 mg\",\n \"ezetimibe-simvastatin\": \"N\/A\"\n },\n \"37-49\": {\n \"simvastatin\": \"40 mg\",\n \"atorvastatin\": \"20 mg\",\n \"rosuvastatin\": \"5 mg\",\n \"fluvastatin\": \"N\/A\",\n \"lovastatin\": \"80 mg\",\n \"pravastatin\": \"80 mg\",\n \"ezetimibe-simvastatin\": \"10 mg + 10 mg\"\n },\n \"49-52\": {\n \"simvastatin\": \"80 mg\",\n \"atorvastatin\": \"40 mg\",\n \"rosuvastatin\": \"10 mg\",\n \"fluvastatin\": \"N\/A\",\n \"lovastatin\": \"N\/A\",\n \"pravastatin\": \"N\/A\",\n \"ezetimibe-simvastatin\": \"10 mg + 20 mg\"\n },\n \"55-60\": {\n \"simvastatin\": \"N\/A\",\n \"atorvastatin\": \"80 mg\",\n \"rosuvastatin\": \"20 mg\",\n \"fluvastatin\": \"N\/A\",\n \"lovastatin\": \"N\/A\",\n \"pravastatin\": \"N\/A\",\n \"ezetimibe-simvastatin\": \"10 mg + 40 mg\"\n },\n \"60-63\": {\n \"simvastatin\": \"N\/A\",\n \"atorvastatin\": \"N\/A\",\n \"rosuvastatin\": \"40 mg\",\n \"fluvastatin\": \"N\/A\",\n \"lovastatin\": \"N\/A\",\n \"pravastatin\": \"N\/A\",\n \"ezetimibe-simvastatin\": \"10 mg + 80 mg\"\n }\n };\n\n \/**\n * Event Listeners Setup\n *\/\n document.addEventListener(\"DOMContentLoaded\", () => {\n const calculateBtn = document.getElementById(\"calculateBtn\");\n const resetBtn = document.getElementById(\"resetBtn\");\n const backBtn = document.getElementById(\"backBtn\");\n const resetResultsBtn = document.getElementById(\"resetResultsBtn\");\n \n calculateBtn.addEventListener(\"click\", showDose);\n resetBtn.addEventListener(\"click\", resetForm);\n backBtn.addEventListener(\"click\", backToForm);\n resetResultsBtn.addEventListener(\"click\", resetForm);\n });\n\n \/**\n * Function to Show the Recommended Dose\n *\/\n function showDose() {\n const ldlRange = document.getElementById(\"ldlRange\").value;\n const statinDrug = document.getElementById(\"statinDrug\").value;\n \n if (!ldlRange || !statinDrug) {\n alert(\"Please select both an LDL Reduction Range and a Statin Drug.\");\n return;\n }\n \n const dose = statinDoseData[ldlRange][statinDrug];\n const displayDose = dose && dose !== \"N\/A\" ? dose : \"N\/A\";\n \n \/\/ Display Selected Values and Dose\n document.getElementById(\"selectedLDL\").textContent = ldlRange + \"%\";\n \n \/\/ Format Statin Drug Display (e.g., \"simvastatin\" to \"Simvastatin (Zocor)\")\n const statinDisplayMap = {\n \"simvastatin\": \"Simvastatin (Zocor)\",\n \"atorvastatin\": \"Atorvastatin (Lipitor)\",\n \"rosuvastatin\": \"Rosuvastatin (Crestor)\",\n \"fluvastatin\": \"Fluvastatin (Lescol)\",\n \"lovastatin\": \"Lovastatin (Mevacor)\",\n \"pravastatin\": \"Pravastatin (Pravachol)\",\n \"ezetimibe-simvastatin\": \"Ezetimibe + Simvastatin (Vytorin)\"\n };\n const statinDisplay = statinDisplayMap[statinDrug] || statinDrug;\n document.getElementById(\"selectedStatin\").textContent = statinDisplay;\n \n document.getElementById(\"doseResult\").textContent = displayDose;\n \n \/\/ Show Results and Hide Form\n document.getElementById(\"form-container\").style.display = \"none\";\n document.getElementById(\"resultsContainer\").style.display = \"block\";\n }\n\n \/**\n * Function to Reset the Form\n *\/\n function resetForm() {\n document.getElementById(\"ldlRange\").value = \"\";\n document.getElementById(\"statinDrug\").value = \"\";\n document.getElementById(\"selectedLDL\").textContent = \"--\";\n document.getElementById(\"selectedStatin\").textContent = \"--\";\n document.getElementById(\"doseResult\").textContent = \"--\";\n \n \/\/ Show Form and Hide Results\n document.getElementById(\"form-container\").style.display = \"block\";\n document.getElementById(\"resultsContainer\").style.display = \"none\";\n }\n\n \/**\n * Function to Navigate Back to the Form from Results\n *\/\n function backToForm() {\n document.getElementById(\"form-container\").style.display = \"block\";\n document.getElementById(\"resultsContainer\").style.display = \"none\";\n }\n<\/script>\n\n<\/body>\n<\/html>\n\n\n\n<p><strong>Table 1.<\/strong> <strong>Steroid Conversion Chart Based on LDL Target<\/strong><\/p>\n\n\n\n<!DOCTYPE html>\n<html lang=\"en\">\n<head>\n <meta charset=\"UTF-8\">\n <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n <title>Equipotential Dose Comparison of Statins<\/title>\n <style>\n table {\n width: 100%;\n border-collapse: collapse;\n margin: 20px 0;\n font-size: 16px;\n text-align: left;\n }\n table th, table td {\n border: 1px solid #ddd;\n padding: 8px;\n }\n table th {\n background-color: #f1f1f1;\n font-weight: bold;\n }\n table tr:nth-child(even) {\n background-color: #f9f9f9;\n }\n table tr:hover {\n background-color: #f1f1f1;\n }\n caption {\n font-size: 18px;\n font-weight: bold;\n margin-bottom: 10px;\n }\n <\/style>\n<\/head>\n<body data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1>\n <table>\n <caption>Equipotential Dose Comparison of Statins<\/caption>\n <thead>\n <tr>\n <th>% LDL Reduction<\/th>\n <th>Simvastatin (Zocor)<\/th>\n <th>Atorvastatin (Lipitor)<\/th>\n <th>Rosuvastatin (Crestor)<\/th>\n <th>Fluvastatin (Lescol)<\/th>\n <th>Lovastatin (Mevacor)<\/th>\n <th>Pravastatin (Pravachol)<\/th>\n <th>Ezetimibe and Simvastatin (Vytorin)<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Less than 24<\/td>\n <td>5mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>20mg<\/td>\n <td>10mg<\/td>\n <td>10mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>25\u201332<\/td>\n <td>10mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>40mg<\/td>\n <td>20mg<\/td>\n <td>20mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>31\u201339<\/td>\n <td>20mg<\/td>\n <td>10mg<\/td>\n <td>\u2014<\/td>\n <td>80mg<\/td>\n <td>40mg<\/td>\n <td>40mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>37\u201349<\/td>\n <td>40mg<\/td>\n <td>20mg<\/td>\n <td>5mg<\/td>\n <td>\u2014<\/td>\n <td>80mg<\/td>\n <td>80mg<\/td>\n <td>10 and 10<\/td>\n <\/tr>\n <tr>\n <td>49\u201352<\/td>\n <td>80mg<\/td>\n <td>40mg<\/td>\n <td>10mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>10 and 20<\/td>\n <\/tr>\n <tr>\n <td>55\u201360<\/td>\n <td>\u2014<\/td>\n <td>80mg<\/td>\n <td>20mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>10 and 40<\/td>\n <\/tr>\n <tr>\n <td>60\u201363<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>40mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>10 and 80<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/body>\n<\/html>\n\n\n\n<h2 class=\"wp-block-heading\">Statins and Clinical Trial Evidence<\/h2>\n\n\n\n<p>Statins, discovered in the 1970s, are cholesterol-lowering drugs that inhibit the enzyme HMG-CoA reductase, a key player in cholesterol synthesis in the liver. This inhibition enhances the liver’s production of LDL receptors, which remove LDL and VLDL cholesterol from the bloodstream, effectively lowering serum cholesterol levels. Statins have proven to be highly effective with relatively few side effects. To date, seven statins have been approved for clinical use. Over the past three decades, numerous randomized controlled trials (RCTs) have demonstrated the efficacy and safety of statin therapy in reducing morbidity and mortality associated with atherosclerotic cardiovascular disease (ASCVD). While individual trials have yielded significant findings, meta-analyses combining data from these trials provide the strongest evidence of statins’ benefits.<\/p>\n\n\n\n<p>Meta-analyses indicate that for every 1 mmol\/L (39 mg\/dL) reduction in LDL-C achieved through statin therapy, there is an approximate 22% reduction in ASCVD events. This relationship holds true across varying levels of LDL-C. However, the efficacy of individual statins varies depending on their intensity of cholesterol-lowering effects. For instance, rosuvastatin is twice as effective as atorvastatin, which itself is twice as effective as simvastatin, on a per-milligram basis. Statins are categorized based on the percentage reduction in LDL-C they achieve, as shown below:<\/p>\n\n\n\n<p><strong>Table 2. Statin intensity therapy<\/strong><\/p>\n\n\n\n<style>\n .statin-table {\n width: 100%;\n border-collapse: collapse;\n margin: 20px 0;\n font-size: 16px;\n text-align: center;\n }\n\n .statin-table th,\n .statin-table td {\n border: 1px solid #dddddd;\n padding: 8px 12px;\n }\n\n .statin-table th {\n background-color: #f4f4f4;\n font-weight: bold;\n }\n\n .statin-table tr:nth-child(even) {\n background-color: #f9f9f9;\n }\n\n .statin-table tr:hover {\n background-color: #f1f1f1;\n }\n<\/style>\n\n<table class=\"statin-table\">\n <thead>\n <tr>\n <th>Drug<\/th>\n <th>Low-Intensity (20\u201325% \u2193 LDL-C)<\/th>\n <th>Moderate-Intensity (30\u201349% \u2193 LDL-C)<\/th>\n <th>High-Intensity (>50% \u2193 LDL-C)<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Lovastatin<\/td>\n <td>10\u201320 mg<\/td>\n <td>40\u201380 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Pravastatin<\/td>\n <td>10\u201320 mg<\/td>\n <td>40\u201380 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Simvastatin<\/td>\n <td>10 mg<\/td>\n <td>20\u201340 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Fluvastatin<\/td>\n <td>20\u201340 mg<\/td>\n <td>80 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Pitavastatin<\/td>\n <td>\u2014<\/td>\n <td>1\u20134 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Atorvastatin<\/td>\n <td>5 mg<\/td>\n <td>10\u201320 mg<\/td>\n <td>40\u201380 mg<\/td>\n <\/tr>\n <tr>\n <td>Rosuvastatin<\/td>\n <td>\u2014<\/td>\n <td>5\u201310 mg<\/td>\n <td>20\u201340 mg<\/td>\n <\/tr>\n <\/tbody>\n<\/table>\n\n\n\n<p>Moderate-intensity statins typically reduce LDL-C by 30\u201349%, lowering ASCVD risk by approximately one-third. High-intensity statins achieve greater reductions (>50%), translating to a risk reduction of about 50%. However, the absolute risk reduction depends on baseline LDL-C levels. For example, a patient with a baseline LDL-C of 200 mg\/dL who achieves a 50% reduction experiences a significant 59% reduction in 10-year ASCVD risk. Conversely, in patients with lower baseline LDL-C levels, the absolute benefit diminishes despite similar percentage reductions. This underscores the principle that while “lower is better,” there are diminishing returns when lowering already low LDL-C levels, necessitating a balance between benefits, risks, and costs.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Non-Statin Cholesterol-Lowering Drugs<\/h3>\n\n\n\n<p>Beyond statins, several other agents are available for cholesterol management, each with unique mechanisms and effects.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bile Acid Sequestrants:<\/strong> These drugs inhibit bile acid absorption in the intestine, thereby upregulating hepatic LDL receptor activity. They moderately reduce LDL-C and have demonstrated efficacy in reducing CHD risk in patients with elevated baseline LDL-C.<\/li>\n\n\n\n<li><strong>Ezetimibe:<\/strong> This agent blocks intestinal cholesterol absorption, enhancing hepatic LDL receptor activity. It lowers LDL-C by 15\u201325% and has shown additive effects when combined with statins. Clinical trials demonstrate its benefit in very high-risk patients, particularly when added to moderate-intensity statin therapy.<\/li>\n\n\n\n<li><strong>Bempedoic Acid:<\/strong> This prodrug inhibits cholesterol synthesis via adenosine triphosphate-citrate lyase (ACL), leading to LDL receptor upregulation. It lowers LDL-C by 15\u201325%, with ongoing trials assessing its cardiovascular benefits.<\/li>\n\n\n\n<li><strong>Niacin and Fibrates:<\/strong> Primarily used for triglyceride reduction, these drugs offer modest LDL-C reductions. Their effects on ASCVD risk vary, with limited incremental benefit when combined with high-intensity statins. Fibrates, particularly fenofibrate, are preferred when used with statins due to a lower risk of myopathy.<\/li>\n\n\n\n<li><strong>Omega-3 Fatty Acids:<\/strong> These lower triglycerides and have shown mixed results in clinical trials. Icosapent ethyl significantly reduced ischemic events in high-risk, hypertriglyceridemic patients when added to statin therapy, whereas other formulations have not demonstrated similar benefits.<\/li>\n<\/ul>\n\n\n\n<p><strong>Table 3. Various non statin cholesterol lowering medications<\/strong><\/p>\n\n\n\n<!DOCTYPE html>\n<html lang=\"en\">\n<head>\n <meta charset=\"UTF-8\">\n \n <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n <title>Non-Statin Cholesterol Lowering Drugs<\/title>\n <style>\n \/* Basic Reset and Styling *\/\n * {\n box-sizing: border-box;\n margin: 0;\n padding: 0;\n }\n body {\n font-family: Arial, sans-serif;\n background-color: #f4f4f9;\n padding: 20px;\n }\n .table-container {\n overflow-x: auto;\n margin: 0 auto;\n max-width: 1000px;\n }\n table {\n width: 100%;\n border-collapse: collapse;\n margin-top: 20px;\n }\n th, td {\n padding: 12px 15px;\n border: 1px solid #ddd;\n text-align: left;\n vertical-align: top;\n }\n th {\n background-color: #e0e0e0; \/* Light gray background for better readability *\/\n color: #000; \/* Black text color for headers *\/\n position: sticky;\n top: 0;\n z-index: 1;\n font-weight: bold;\n }\n tr:nth-child(even) {\n background-color: #f9f9f9;\n }\n tr:hover {\n background-color: #f1f1f1;\n }\n caption {\n caption-side: top;\n font-size: 1.5em;\n margin-bottom: 10px;\n color: #333;\n font-weight: bold;\n }\n .bullet-list {\n list-style-type: disc;\n padding-left: 20px;\n margin-top: 5px;\n }\n @media (max-width: 768px) {\n th, td {\n padding: 8px 10px;\n font-size: 14px;\n }\n caption {\n font-size: 1.2em;\n }\n }\n <\/style>\n<\/head>\n<body data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1>\n\n <div class=\"table-container\">\n <table>\n <caption>Non-Statin Cholesterol Lowering Drugs<\/caption>\n <thead>\n <tr>\n <th>Drug Class<\/th>\n <th>Mechanism of Action<\/th>\n <th>Effects on Plasma Lipids<\/th>\n <th>LDL-C Lowering<\/th>\n <th>Side Effects<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Bile Acid Sequestrants<\/td>\n <td>Impairs reabsorption of bile acids<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Raise LDL receptor activity<\/li>\n <li>Reduces LDL<\/li>\n <li>Raises VLDL<\/li>\n <li>Minimal effect on HDL<\/li>\n <li>15-25%, depending on dose<\/li>\n <\/ul>\n <\/td>\n <td>15-25%<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Constipation<\/li>\n <li>GI distress<\/li>\n <li>Increases TG<\/li>\n <\/ul>\n <\/td>\n <\/tr>\n <tr>\n <td>Ezetimibe<\/td>\n <td>Impairs absorption of cholesterol<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Raises LDL receptor activity<\/li>\n <li>Reduces LDL<\/li>\n <li>Reduces VLDL<\/li>\n <li>Minimal effect on HDL<\/li>\n <li>15-25%<\/li>\n <\/ul>\n <\/td>\n <td>15-25%<\/td>\n <td>Rare<\/td>\n <\/tr>\n <tr>\n <td>Bempedoic Acid<\/td>\n <td>Inhibitor of ATP-citrate lyase leading to decreased cholesterol synthesis and an increase in LDL receptor activity<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Reduces LDL<\/li>\n <li>15-25%<\/li>\n <\/ul>\n <\/td>\n <td>15-25%<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Increases uric acid leading to gout<\/li>\n <li>Tendon rupture has been reported<\/li>\n <\/ul>\n <\/td>\n <\/tr>\n <tr>\n <td>Niacin<\/td>\n <td>Reduces hepatic secretion of VLDL<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Reduces VLDL<\/li>\n <li>Reduces LDL<\/li>\n <li>Raises HDL<\/li>\n <li>5-20%<\/li>\n <\/ul>\n <\/td>\n <td>5-20%<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Flushing<\/li>\n <li>Rash<\/li>\n <li>Raise plasma glucose<\/li>\n <li>Hepatic dysfunction<\/li>\n <li>Others<\/li>\n <\/ul>\n <\/td>\n <\/tr>\n <tr>\n <td>Fibrates<\/td>\n <td>Reduces secretion of VLDL<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Enhances degradation of VLDL<\/li>\n <li>Reduces VLDL (lowers TG 25-35%)<\/li>\n <li>Small effect on LDL<\/li>\n <li>Raises HDL<\/li>\n <li>5-15%<\/li>\n <\/ul>\n <\/td>\n <td>5-15%<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Myopathy (in combination with statins)<\/li>\n <li>Gallstones<\/li>\n <li>Uncommonly various others<\/li>\n <\/ul>\n <\/td>\n <\/tr>\n <tr>\n <td>MTP Inhibitors<\/td>\n <td>Approved for treatment of homozygous familial hypercholesterolemia<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Reduces hepatic secretion of VLDL<\/li>\n <li>Reduces VLDL and LDL<\/li>\n <li>50+%<\/li>\n <\/ul>\n <\/td>\n <td>50+%<\/td>\n <td>Fatty liver<\/td>\n <\/tr>\n <tr>\n <td>Mipomersen (RNA Antisense)<\/td>\n <td>No longer available<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Reduces hepatic secretion of VLDL<\/li>\n <li>Reduces VLDL and LDL<\/li>\n <li>50+%<\/li>\n <\/ul>\n <\/td>\n <td>50+%<\/td>\n <td>Fatty liver<\/td>\n <\/tr>\n <tr>\n <td>CETP Inhibitors<\/td>\n <td>Not approved by FDA<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Blocks transfer of cholesterol from HDL to VLDL & LDL<\/li>\n <li>Raises HDL<\/li>\n <li>Lowers LDL<\/li>\n <li>20-30%<\/li>\n <\/ul>\n <\/td>\n <td>20-30%<\/td>\n <td><\/td>\n <\/tr>\n <tr>\n <td>PCSK9 Inhibitors<\/td>\n <td>Recommended for ASCVD patients at high risk<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Blocks effects of PCSK9 to destroy LDL receptors<\/li>\n <li>Lowers LDL<\/li>\n <li>45-60%<\/li>\n <\/ul>\n <\/td>\n <td>45-60%<\/td>\n <td><\/td>\n <\/tr>\n <tr>\n <td>Evinacumab<\/td>\n <td>Approved for treatment of homozygous familial hypercholesterolemia<br>Blocks angiopoietin-like protein 3 (ANGPTL3)<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Lowers LDL<\/li>\n <li>Lowers TG (~50%)<\/li>\n <li>Lowers HDL (~30%)<\/li>\n <li>Approx. 50%<\/li>\n <\/ul>\n <\/td>\n <td>Approx. 50%<\/td>\n <td><\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n<\/body>\n<\/html>\n\n\n\n<p>Other emerging therapies include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PCSK9 Inhibitors:<\/strong> These drugs inhibit a protein that promotes LDL receptor degradation, resulting in substantial LDL-C reductions. They are effective in high-risk ASCVD patients, particularly those with statin intolerance or very high baseline LDL-C.<\/li>\n\n\n\n<li><strong>Evinacumab:<\/strong> A monoclonal antibody targeting ANGPTL3, this drug is approved for homozygous familial hypercholesterolemia, reducing LDL-C independently of LDL receptor activity.<\/li>\n\n\n\n<li><strong>CETP Inhibitors:<\/strong> Although these drugs lower LDL-C and raise HDL-C, clinical trials have shown minimal benefits, and they are not currently FDA-approved.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Reference<\/h2>\n\n\n\n<p>Smith MEB, Lee NJ, Haney E, et al. Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet]. Portland (OR): Oregon Health & Science University; 2009 Nov. Available from: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK47273\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK47273\/<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Statin Conversion Calculator Statin Conversion Calculator Select LDL Reduction and Statin Drug %LDL Reduction Range –Select LDL Reduction Range–Less than 24%25\u201332%31\u201339%37\u201349%49\u201352%55\u201360%60\u201363% Statin Drug –Select Statin Drug–Simvastatin (Zocor)Atorvastatin (Lipitor)Rosuvastatin (Crestor)Fluvastatin (Lescol)Lovastatin (Mevacor)Pravastatin (Pravachol)Ezetimibe + Simvastatin (Vytorin) Show Estimated Dose Reset Estimated Statin Dose Selected %LDL Reduction Range: — Selected Statin Drug: — Recommended Dose: — Back […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[100],"tags":[],"class_list":["post-4421785","post","type-post","status-publish","format-standard","hentry","category-endocalculator","post-wrapper","thrv_wrapper"],"_links":{"self":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/posts\/4421785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/comments?post=4421785"}],"version-history":[{"count":19,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/posts\/4421785\/revisions"}],"predecessor-version":[{"id":4421810,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/posts\/4421785\/revisions\/4421810"}],"wp:attachment":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/media?parent=4421785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/categories?post=4421785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/tags?post=4421785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

{"id":4421785,"date":"2024-12-25T06:28:37","date_gmt":"2024-12-25T12:28:37","guid":{"rendered":"https:\/\/myendoconsult.com\/learn\/?p=4421785"},"modified":"2024-12-25T07:20:39","modified_gmt":"2024-12-25T13:20:39","slug":"statin-conversion-chart","status":"publish","type":"post","link":"https:\/\/myendoconsult.com\/learn\/statin-conversion-chart\/","title":{"rendered":"Statin Conversion Chart"},"content":{"rendered":"\n\n\n\n \n \n \n Statin Conversion Calculator<\/title>\n <style>\n \/* Basic Reset and Styling *\/\n * {\n box-sizing: border-box;\n margin: 0;\n padding: 0;\n }\n body {\n font-family: Arial, sans-serif;\n background-color: #f4f4f9;\n padding: 20px;\n }\n .calculator-container {\n max-width: 600px;\n margin: 0 auto;\n padding: 25px;\n background: #fff;\n border-radius: 10px;\n box-shadow: 0 2px 10px rgba(0,0,0,0.1);\n }\n h1, h2 {\n text-align: center;\n color: #333;\n margin-bottom: 20px;\n }\n label {\n display: block;\n font-weight: bold;\n margin-top: 15px;\n color: #333;\n }\n select {\n width: 100%;\n padding: 10px;\n margin-top: 5px;\n margin-bottom: 15px;\n border: 1px solid #ccc;\n border-radius: 5px;\n font-size: 16px;\n }\n .button-row {\n display: flex;\n justify-content: space-between;\n gap: 10px;\n margin-top: 20px;\n }\n button {\n flex: 1;\n padding: 12px 0;\n background-color: #0073aa;\n color: white;\n border: none;\n border-radius: 5px;\n font-size: 16px;\n cursor: pointer;\n transition: background-color 0.3s ease;\n }\n button:hover {\n background-color: #005177;\n }\n .results-container {\n margin-top: 30px;\n padding: 20px;\n background: #f9f9f9;\n border-radius: 8px;\n text-align: center;\n display: none;\n }\n .result-label {\n font-weight: bold;\n color: #333;\n margin-top: 10px;\n }\n .result-value {\n font-size: 20px;\n color: #d9534f;\n margin-bottom: 15px;\n }\n @media (max-width: 600px) {\n .button-row {\n flex-direction: column;\n }\n button {\n margin-top: 10px;\n }\n }\n <\/style>\n<\/head>\n<body data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1>\n\n<div class=\"calculator-container\">\n <h1>Statin Conversion Calculator<\/h1>\n <div id=\"form-container\">\n <h2>Select LDL Reduction and Statin Drug<\/h2>\n \n \n <label for=\"ldlRange\">%LDL Reduction Range<\/label>\n <select id=\"ldlRange\">\n <option value=\"\">–Select LDL Reduction Range–<\/option>\n <option value=\"<24\">Less than 24%<\/option>\n <option value=\"25-32\">25\u201332%<\/option>\n <option value=\"31-39\">31\u201339%<\/option>\n <option value=\"37-49\">37\u201349%<\/option>\n <option value=\"49-52\">49\u201352%<\/option>\n <option value=\"55-60\">55\u201360%<\/option>\n <option value=\"60-63\">60\u201363%<\/option>\n <\/select>\n \n \n <label for=\"statinDrug\">Statin Drug<\/label>\n <select id=\"statinDrug\">\n <option value=\"\">–Select Statin Drug–<\/option>\n <option value=\"simvastatin\">Simvastatin (Zocor)<\/option>\n <option value=\"atorvastatin\">Atorvastatin (Lipitor)<\/option>\n <option value=\"rosuvastatin\">Rosuvastatin (Crestor)<\/option>\n <option value=\"fluvastatin\">Fluvastatin (Lescol)<\/option>\n <option value=\"lovastatin\">Lovastatin (Mevacor)<\/option>\n <option value=\"pravastatin\">Pravastatin (Pravachol)<\/option>\n <option value=\"ezetimibe-simvastatin\">Ezetimibe + Simvastatin (Vytorin)<\/option>\n <\/select>\n \n \n <div class=\"button-row\">\n <button id=\"calculateBtn\" type=\"button\">Show Estimated Dose<\/button>\n <button id=\"resetBtn\" type=\"button\">Reset<\/button>\n <\/div>\n <\/div>\n \n \n <div class=\"results-container\" id=\"resultsContainer\">\n <h2>Estimated Statin Dose<\/h2>\n <div class=\"results\">\n <p class=\"result-label\">Selected %LDL Reduction Range:<\/p>\n <div class=\"result-value\" id=\"selectedLDL\">—<\/div>\n \n <p class=\"result-label\">Selected Statin Drug:<\/p>\n <div class=\"result-value\" id=\"selectedStatin\">—<\/div>\n \n <p class=\"result-label\">Recommended Dose:<\/p>\n <div class=\"result-value\" id=\"doseResult\">—<\/div>\n <\/div>\n <div class=\"button-row\">\n <button id=\"backBtn\" type=\"button\">Back<\/button>\n <button id=\"resetResultsBtn\" type=\"button\">Reset<\/button>\n <\/div>\n <\/div>\n<\/div>\n\n<script>\n \/**\n * Data Mapping for %LDL Reduction and Statin Doses\n *\/\n const statinDoseData = {\n \"<24\": {\n \"simvastatin\": \"5 mg\",\n \"atorvastatin\": \"N\/A\",\n \"rosuvastatin\": \"N\/A\",\n \"fluvastatin\": \"20 mg\",\n \"lovastatin\": \"10 mg\",\n \"pravastatin\": \"10 mg\",\n \"ezetimibe-simvastatin\": \"N\/A\"\n },\n \"25-32\": {\n \"simvastatin\": \"10 mg\",\n \"atorvastatin\": \"N\/A\",\n \"rosuvastatin\": \"N\/A\",\n \"fluvastatin\": \"40 mg\",\n \"lovastatin\": \"20 mg\",\n \"pravastatin\": \"20 mg\",\n \"ezetimibe-simvastatin\": \"N\/A\"\n },\n \"31-39\": {\n \"simvastatin\": \"20 mg\",\n \"atorvastatin\": \"10 mg\",\n \"rosuvastatin\": \"N\/A\",\n \"fluvastatin\": \"80 mg\",\n \"lovastatin\": \"40 mg\",\n \"pravastatin\": \"40 mg\",\n \"ezetimibe-simvastatin\": \"N\/A\"\n },\n \"37-49\": {\n \"simvastatin\": \"40 mg\",\n \"atorvastatin\": \"20 mg\",\n \"rosuvastatin\": \"5 mg\",\n \"fluvastatin\": \"N\/A\",\n \"lovastatin\": \"80 mg\",\n \"pravastatin\": \"80 mg\",\n \"ezetimibe-simvastatin\": \"10 mg + 10 mg\"\n },\n \"49-52\": {\n \"simvastatin\": \"80 mg\",\n \"atorvastatin\": \"40 mg\",\n \"rosuvastatin\": \"10 mg\",\n \"fluvastatin\": \"N\/A\",\n \"lovastatin\": \"N\/A\",\n \"pravastatin\": \"N\/A\",\n \"ezetimibe-simvastatin\": \"10 mg + 20 mg\"\n },\n \"55-60\": {\n \"simvastatin\": \"N\/A\",\n \"atorvastatin\": \"80 mg\",\n \"rosuvastatin\": \"20 mg\",\n \"fluvastatin\": \"N\/A\",\n \"lovastatin\": \"N\/A\",\n \"pravastatin\": \"N\/A\",\n \"ezetimibe-simvastatin\": \"10 mg + 40 mg\"\n },\n \"60-63\": {\n \"simvastatin\": \"N\/A\",\n \"atorvastatin\": \"N\/A\",\n \"rosuvastatin\": \"40 mg\",\n \"fluvastatin\": \"N\/A\",\n \"lovastatin\": \"N\/A\",\n \"pravastatin\": \"N\/A\",\n \"ezetimibe-simvastatin\": \"10 mg + 80 mg\"\n }\n };\n\n \/**\n * Event Listeners Setup\n *\/\n document.addEventListener(\"DOMContentLoaded\", () => {\n const calculateBtn = document.getElementById(\"calculateBtn\");\n const resetBtn = document.getElementById(\"resetBtn\");\n const backBtn = document.getElementById(\"backBtn\");\n const resetResultsBtn = document.getElementById(\"resetResultsBtn\");\n \n calculateBtn.addEventListener(\"click\", showDose);\n resetBtn.addEventListener(\"click\", resetForm);\n backBtn.addEventListener(\"click\", backToForm);\n resetResultsBtn.addEventListener(\"click\", resetForm);\n });\n\n \/**\n * Function to Show the Recommended Dose\n *\/\n function showDose() {\n const ldlRange = document.getElementById(\"ldlRange\").value;\n const statinDrug = document.getElementById(\"statinDrug\").value;\n \n if (!ldlRange || !statinDrug) {\n alert(\"Please select both an LDL Reduction Range and a Statin Drug.\");\n return;\n }\n \n const dose = statinDoseData[ldlRange][statinDrug];\n const displayDose = dose && dose !== \"N\/A\" ? dose : \"N\/A\";\n \n \/\/ Display Selected Values and Dose\n document.getElementById(\"selectedLDL\").textContent = ldlRange + \"%\";\n \n \/\/ Format Statin Drug Display (e.g., \"simvastatin\" to \"Simvastatin (Zocor)\")\n const statinDisplayMap = {\n \"simvastatin\": \"Simvastatin (Zocor)\",\n \"atorvastatin\": \"Atorvastatin (Lipitor)\",\n \"rosuvastatin\": \"Rosuvastatin (Crestor)\",\n \"fluvastatin\": \"Fluvastatin (Lescol)\",\n \"lovastatin\": \"Lovastatin (Mevacor)\",\n \"pravastatin\": \"Pravastatin (Pravachol)\",\n \"ezetimibe-simvastatin\": \"Ezetimibe + Simvastatin (Vytorin)\"\n };\n const statinDisplay = statinDisplayMap[statinDrug] || statinDrug;\n document.getElementById(\"selectedStatin\").textContent = statinDisplay;\n \n document.getElementById(\"doseResult\").textContent = displayDose;\n \n \/\/ Show Results and Hide Form\n document.getElementById(\"form-container\").style.display = \"none\";\n document.getElementById(\"resultsContainer\").style.display = \"block\";\n }\n\n \/**\n * Function to Reset the Form\n *\/\n function resetForm() {\n document.getElementById(\"ldlRange\").value = \"\";\n document.getElementById(\"statinDrug\").value = \"\";\n document.getElementById(\"selectedLDL\").textContent = \"--\";\n document.getElementById(\"selectedStatin\").textContent = \"--\";\n document.getElementById(\"doseResult\").textContent = \"--\";\n \n \/\/ Show Form and Hide Results\n document.getElementById(\"form-container\").style.display = \"block\";\n document.getElementById(\"resultsContainer\").style.display = \"none\";\n }\n\n \/**\n * Function to Navigate Back to the Form from Results\n *\/\n function backToForm() {\n document.getElementById(\"form-container\").style.display = \"block\";\n document.getElementById(\"resultsContainer\").style.display = \"none\";\n }\n<\/script>\n\n<\/body>\n<\/html>\n\n\n\n<p><strong>Table 1.<\/strong> <strong>Steroid Conversion Chart Based on LDL Target<\/strong><\/p>\n\n\n\n<!DOCTYPE html>\n<html lang=\"en\">\n<head>\n <meta charset=\"UTF-8\">\n <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n <title>Equipotential Dose Comparison of Statins<\/title>\n <style>\n table {\n width: 100%;\n border-collapse: collapse;\n margin: 20px 0;\n font-size: 16px;\n text-align: left;\n }\n table th, table td {\n border: 1px solid #ddd;\n padding: 8px;\n }\n table th {\n background-color: #f1f1f1;\n font-weight: bold;\n }\n table tr:nth-child(even) {\n background-color: #f9f9f9;\n }\n table tr:hover {\n background-color: #f1f1f1;\n }\n caption {\n font-size: 18px;\n font-weight: bold;\n margin-bottom: 10px;\n }\n <\/style>\n<\/head>\n<body data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1>\n <table>\n <caption>Equipotential Dose Comparison of Statins<\/caption>\n <thead>\n <tr>\n <th>% LDL Reduction<\/th>\n <th>Simvastatin (Zocor)<\/th>\n <th>Atorvastatin (Lipitor)<\/th>\n <th>Rosuvastatin (Crestor)<\/th>\n <th>Fluvastatin (Lescol)<\/th>\n <th>Lovastatin (Mevacor)<\/th>\n <th>Pravastatin (Pravachol)<\/th>\n <th>Ezetimibe and Simvastatin (Vytorin)<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Less than 24<\/td>\n <td>5mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>20mg<\/td>\n <td>10mg<\/td>\n <td>10mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>25\u201332<\/td>\n <td>10mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>40mg<\/td>\n <td>20mg<\/td>\n <td>20mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>31\u201339<\/td>\n <td>20mg<\/td>\n <td>10mg<\/td>\n <td>\u2014<\/td>\n <td>80mg<\/td>\n <td>40mg<\/td>\n <td>40mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>37\u201349<\/td>\n <td>40mg<\/td>\n <td>20mg<\/td>\n <td>5mg<\/td>\n <td>\u2014<\/td>\n <td>80mg<\/td>\n <td>80mg<\/td>\n <td>10 and 10<\/td>\n <\/tr>\n <tr>\n <td>49\u201352<\/td>\n <td>80mg<\/td>\n <td>40mg<\/td>\n <td>10mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>10 and 20<\/td>\n <\/tr>\n <tr>\n <td>55\u201360<\/td>\n <td>\u2014<\/td>\n <td>80mg<\/td>\n <td>20mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>10 and 40<\/td>\n <\/tr>\n <tr>\n <td>60\u201363<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>40mg<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>\u2014<\/td>\n <td>10 and 80<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n<\/body>\n<\/html>\n\n\n\n<h2 class=\"wp-block-heading\">Statins and Clinical Trial Evidence<\/h2>\n\n\n\n<p>Statins, discovered in the 1970s, are cholesterol-lowering drugs that inhibit the enzyme HMG-CoA reductase, a key player in cholesterol synthesis in the liver. This inhibition enhances the liver’s production of LDL receptors, which remove LDL and VLDL cholesterol from the bloodstream, effectively lowering serum cholesterol levels. Statins have proven to be highly effective with relatively few side effects. To date, seven statins have been approved for clinical use. Over the past three decades, numerous randomized controlled trials (RCTs) have demonstrated the efficacy and safety of statin therapy in reducing morbidity and mortality associated with atherosclerotic cardiovascular disease (ASCVD). While individual trials have yielded significant findings, meta-analyses combining data from these trials provide the strongest evidence of statins’ benefits.<\/p>\n\n\n\n<p>Meta-analyses indicate that for every 1 mmol\/L (39 mg\/dL) reduction in LDL-C achieved through statin therapy, there is an approximate 22% reduction in ASCVD events. This relationship holds true across varying levels of LDL-C. However, the efficacy of individual statins varies depending on their intensity of cholesterol-lowering effects. For instance, rosuvastatin is twice as effective as atorvastatin, which itself is twice as effective as simvastatin, on a per-milligram basis. Statins are categorized based on the percentage reduction in LDL-C they achieve, as shown below:<\/p>\n\n\n\n<p><strong>Table 2. Statin intensity therapy<\/strong><\/p>\n\n\n\n<style>\n .statin-table {\n width: 100%;\n border-collapse: collapse;\n margin: 20px 0;\n font-size: 16px;\n text-align: center;\n }\n\n .statin-table th,\n .statin-table td {\n border: 1px solid #dddddd;\n padding: 8px 12px;\n }\n\n .statin-table th {\n background-color: #f4f4f4;\n font-weight: bold;\n }\n\n .statin-table tr:nth-child(even) {\n background-color: #f9f9f9;\n }\n\n .statin-table tr:hover {\n background-color: #f1f1f1;\n }\n<\/style>\n\n<table class=\"statin-table\">\n <thead>\n <tr>\n <th>Drug<\/th>\n <th>Low-Intensity (20\u201325% \u2193 LDL-C)<\/th>\n <th>Moderate-Intensity (30\u201349% \u2193 LDL-C)<\/th>\n <th>High-Intensity (>50% \u2193 LDL-C)<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Lovastatin<\/td>\n <td>10\u201320 mg<\/td>\n <td>40\u201380 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Pravastatin<\/td>\n <td>10\u201320 mg<\/td>\n <td>40\u201380 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Simvastatin<\/td>\n <td>10 mg<\/td>\n <td>20\u201340 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Fluvastatin<\/td>\n <td>20\u201340 mg<\/td>\n <td>80 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Pitavastatin<\/td>\n <td>\u2014<\/td>\n <td>1\u20134 mg<\/td>\n <td>\u2014<\/td>\n <\/tr>\n <tr>\n <td>Atorvastatin<\/td>\n <td>5 mg<\/td>\n <td>10\u201320 mg<\/td>\n <td>40\u201380 mg<\/td>\n <\/tr>\n <tr>\n <td>Rosuvastatin<\/td>\n <td>\u2014<\/td>\n <td>5\u201310 mg<\/td>\n <td>20\u201340 mg<\/td>\n <\/tr>\n <\/tbody>\n<\/table>\n\n\n\n<p>Moderate-intensity statins typically reduce LDL-C by 30\u201349%, lowering ASCVD risk by approximately one-third. High-intensity statins achieve greater reductions (>50%), translating to a risk reduction of about 50%. However, the absolute risk reduction depends on baseline LDL-C levels. For example, a patient with a baseline LDL-C of 200 mg\/dL who achieves a 50% reduction experiences a significant 59% reduction in 10-year ASCVD risk. Conversely, in patients with lower baseline LDL-C levels, the absolute benefit diminishes despite similar percentage reductions. This underscores the principle that while “lower is better,” there are diminishing returns when lowering already low LDL-C levels, necessitating a balance between benefits, risks, and costs.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Non-Statin Cholesterol-Lowering Drugs<\/h3>\n\n\n\n<p>Beyond statins, several other agents are available for cholesterol management, each with unique mechanisms and effects.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bile Acid Sequestrants:<\/strong> These drugs inhibit bile acid absorption in the intestine, thereby upregulating hepatic LDL receptor activity. They moderately reduce LDL-C and have demonstrated efficacy in reducing CHD risk in patients with elevated baseline LDL-C.<\/li>\n\n\n\n<li><strong>Ezetimibe:<\/strong> This agent blocks intestinal cholesterol absorption, enhancing hepatic LDL receptor activity. It lowers LDL-C by 15\u201325% and has shown additive effects when combined with statins. Clinical trials demonstrate its benefit in very high-risk patients, particularly when added to moderate-intensity statin therapy.<\/li>\n\n\n\n<li><strong>Bempedoic Acid:<\/strong> This prodrug inhibits cholesterol synthesis via adenosine triphosphate-citrate lyase (ACL), leading to LDL receptor upregulation. It lowers LDL-C by 15\u201325%, with ongoing trials assessing its cardiovascular benefits.<\/li>\n\n\n\n<li><strong>Niacin and Fibrates:<\/strong> Primarily used for triglyceride reduction, these drugs offer modest LDL-C reductions. Their effects on ASCVD risk vary, with limited incremental benefit when combined with high-intensity statins. Fibrates, particularly fenofibrate, are preferred when used with statins due to a lower risk of myopathy.<\/li>\n\n\n\n<li><strong>Omega-3 Fatty Acids:<\/strong> These lower triglycerides and have shown mixed results in clinical trials. Icosapent ethyl significantly reduced ischemic events in high-risk, hypertriglyceridemic patients when added to statin therapy, whereas other formulations have not demonstrated similar benefits.<\/li>\n<\/ul>\n\n\n\n<p><strong>Table 3. Various non statin cholesterol lowering medications<\/strong><\/p>\n\n\n\n<!DOCTYPE html>\n<html lang=\"en\">\n<head>\n <meta charset=\"UTF-8\">\n \n <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n <title>Non-Statin Cholesterol Lowering Drugs<\/title>\n <style>\n \/* Basic Reset and Styling *\/\n * {\n box-sizing: border-box;\n margin: 0;\n padding: 0;\n }\n body {\n font-family: Arial, sans-serif;\n background-color: #f4f4f9;\n padding: 20px;\n }\n .table-container {\n overflow-x: auto;\n margin: 0 auto;\n max-width: 1000px;\n }\n table {\n width: 100%;\n border-collapse: collapse;\n margin-top: 20px;\n }\n th, td {\n padding: 12px 15px;\n border: 1px solid #ddd;\n text-align: left;\n vertical-align: top;\n }\n th {\n background-color: #e0e0e0; \/* Light gray background for better readability *\/\n color: #000; \/* Black text color for headers *\/\n position: sticky;\n top: 0;\n z-index: 1;\n font-weight: bold;\n }\n tr:nth-child(even) {\n background-color: #f9f9f9;\n }\n tr:hover {\n background-color: #f1f1f1;\n }\n caption {\n caption-side: top;\n font-size: 1.5em;\n margin-bottom: 10px;\n color: #333;\n font-weight: bold;\n }\n .bullet-list {\n list-style-type: disc;\n padding-left: 20px;\n margin-top: 5px;\n }\n @media (max-width: 768px) {\n th, td {\n padding: 8px 10px;\n font-size: 14px;\n }\n caption {\n font-size: 1.2em;\n }\n }\n <\/style>\n<\/head>\n<body data-rsssl=1 data-rsssl=1 data-rsssl=1 data-rsssl=1>\n\n <div class=\"table-container\">\n <table>\n <caption>Non-Statin Cholesterol Lowering Drugs<\/caption>\n <thead>\n <tr>\n <th>Drug Class<\/th>\n <th>Mechanism of Action<\/th>\n <th>Effects on Plasma Lipids<\/th>\n <th>LDL-C Lowering<\/th>\n <th>Side Effects<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <td>Bile Acid Sequestrants<\/td>\n <td>Impairs reabsorption of bile acids<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Raise LDL receptor activity<\/li>\n <li>Reduces LDL<\/li>\n <li>Raises VLDL<\/li>\n <li>Minimal effect on HDL<\/li>\n <li>15-25%, depending on dose<\/li>\n <\/ul>\n <\/td>\n <td>15-25%<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Constipation<\/li>\n <li>GI distress<\/li>\n <li>Increases TG<\/li>\n <\/ul>\n <\/td>\n <\/tr>\n <tr>\n <td>Ezetimibe<\/td>\n <td>Impairs absorption of cholesterol<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Raises LDL receptor activity<\/li>\n <li>Reduces LDL<\/li>\n <li>Reduces VLDL<\/li>\n <li>Minimal effect on HDL<\/li>\n <li>15-25%<\/li>\n <\/ul>\n <\/td>\n <td>15-25%<\/td>\n <td>Rare<\/td>\n <\/tr>\n <tr>\n <td>Bempedoic Acid<\/td>\n <td>Inhibitor of ATP-citrate lyase leading to decreased cholesterol synthesis and an increase in LDL receptor activity<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Reduces LDL<\/li>\n <li>15-25%<\/li>\n <\/ul>\n <\/td>\n <td>15-25%<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Increases uric acid leading to gout<\/li>\n <li>Tendon rupture has been reported<\/li>\n <\/ul>\n <\/td>\n <\/tr>\n <tr>\n <td>Niacin<\/td>\n <td>Reduces hepatic secretion of VLDL<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Reduces VLDL<\/li>\n <li>Reduces LDL<\/li>\n <li>Raises HDL<\/li>\n <li>5-20%<\/li>\n <\/ul>\n <\/td>\n <td>5-20%<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Flushing<\/li>\n <li>Rash<\/li>\n <li>Raise plasma glucose<\/li>\n <li>Hepatic dysfunction<\/li>\n <li>Others<\/li>\n <\/ul>\n <\/td>\n <\/tr>\n <tr>\n <td>Fibrates<\/td>\n <td>Reduces secretion of VLDL<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Enhances degradation of VLDL<\/li>\n <li>Reduces VLDL (lowers TG 25-35%)<\/li>\n <li>Small effect on LDL<\/li>\n <li>Raises HDL<\/li>\n <li>5-15%<\/li>\n <\/ul>\n <\/td>\n <td>5-15%<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Myopathy (in combination with statins)<\/li>\n <li>Gallstones<\/li>\n <li>Uncommonly various others<\/li>\n <\/ul>\n <\/td>\n <\/tr>\n <tr>\n <td>MTP Inhibitors<\/td>\n <td>Approved for treatment of homozygous familial hypercholesterolemia<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Reduces hepatic secretion of VLDL<\/li>\n <li>Reduces VLDL and LDL<\/li>\n <li>50+%<\/li>\n <\/ul>\n <\/td>\n <td>50+%<\/td>\n <td>Fatty liver<\/td>\n <\/tr>\n <tr>\n <td>Mipomersen (RNA Antisense)<\/td>\n <td>No longer available<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Reduces hepatic secretion of VLDL<\/li>\n <li>Reduces VLDL and LDL<\/li>\n <li>50+%<\/li>\n <\/ul>\n <\/td>\n <td>50+%<\/td>\n <td>Fatty liver<\/td>\n <\/tr>\n <tr>\n <td>CETP Inhibitors<\/td>\n <td>Not approved by FDA<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Blocks transfer of cholesterol from HDL to VLDL & LDL<\/li>\n <li>Raises HDL<\/li>\n <li>Lowers LDL<\/li>\n <li>20-30%<\/li>\n <\/ul>\n <\/td>\n <td>20-30%<\/td>\n <td><\/td>\n <\/tr>\n <tr>\n <td>PCSK9 Inhibitors<\/td>\n <td>Recommended for ASCVD patients at high risk<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Blocks effects of PCSK9 to destroy LDL receptors<\/li>\n <li>Lowers LDL<\/li>\n <li>45-60%<\/li>\n <\/ul>\n <\/td>\n <td>45-60%<\/td>\n <td><\/td>\n <\/tr>\n <tr>\n <td>Evinacumab<\/td>\n <td>Approved for treatment of homozygous familial hypercholesterolemia<br>Blocks angiopoietin-like protein 3 (ANGPTL3)<\/td>\n <td>\n <ul class=\"bullet-list\">\n <li>Lowers LDL<\/li>\n <li>Lowers TG (~50%)<\/li>\n <li>Lowers HDL (~30%)<\/li>\n <li>Approx. 50%<\/li>\n <\/ul>\n <\/td>\n <td>Approx. 50%<\/td>\n <td><\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n<\/body>\n<\/html>\n\n\n\n<p>Other emerging therapies include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PCSK9 Inhibitors:<\/strong> These drugs inhibit a protein that promotes LDL receptor degradation, resulting in substantial LDL-C reductions. They are effective in high-risk ASCVD patients, particularly those with statin intolerance or very high baseline LDL-C.<\/li>\n\n\n\n<li><strong>Evinacumab:<\/strong> A monoclonal antibody targeting ANGPTL3, this drug is approved for homozygous familial hypercholesterolemia, reducing LDL-C independently of LDL receptor activity.<\/li>\n\n\n\n<li><strong>CETP Inhibitors:<\/strong> Although these drugs lower LDL-C and raise HDL-C, clinical trials have shown minimal benefits, and they are not currently FDA-approved.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Reference<\/h2>\n\n\n\n<p>Smith MEB, Lee NJ, Haney E, et al. Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet]. Portland (OR): Oregon Health & Science University; 2009 Nov. Available from: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK47273\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK47273\/<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Statin Conversion Calculator Statin Conversion Calculator Select LDL Reduction and Statin Drug %LDL Reduction Range –Select LDL Reduction Range–Less than 24%25\u201332%31\u201339%37\u201349%49\u201352%55\u201360%60\u201363% Statin Drug –Select Statin Drug–Simvastatin (Zocor)Atorvastatin (Lipitor)Rosuvastatin (Crestor)Fluvastatin (Lescol)Lovastatin (Mevacor)Pravastatin (Pravachol)Ezetimibe + Simvastatin (Vytorin) Show Estimated Dose Reset Estimated Statin Dose Selected %LDL Reduction Range: — Selected Statin Drug: — Recommended Dose: — Back […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[100],"tags":[],"class_list":["post-4421785","post","type-post","status-publish","format-standard","hentry","category-endocalculator","post-wrapper","thrv_wrapper"],"_links":{"self":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/posts\/4421785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/comments?post=4421785"}],"version-history":[{"count":19,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/posts\/4421785\/revisions"}],"predecessor-version":[{"id":4421810,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/posts\/4421785\/revisions\/4421810"}],"wp:attachment":[{"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/media?parent=4421785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/categories?post=4421785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myendoconsult.com\/learn\/wp-json\/wp\/v2\/tags?post=4421785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}